Yestar Healthcare Holdings Co Ltd (HK:2393)
:2393
Want to see HK:2393 full AI Analyst Report?
2393 Stock Chart & Stats
HK$0.10
HK$0.00(0.00%)
At close: 4:00 PM EST
HK$0.10
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$0.07 - HK$0.20
Previous CloseN/A
Volume710.00K
Average Volume (3M)2.34M
Market Cap
HK$174.72M
Enterprise ValueHK$113.49M
Total Cash (Recent Filing)HK$234.51M
Total Debt (Recent Filing)HK$211.05M
Price to Earnings (P/E)―
Beta0.52
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding2,331,590,000
10 Day Avg. Volume1,184,000
30 Day Avg. Volume2,342,546
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.56
Price to Sales (P/S)0.14
P/FCF Ratio0.73
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet HealthThe company materially improved its balance sheet, returning to positive equity and cutting total debt so leverage sits around 0.56. This durable improvement enhances financial flexibility, reduces refinancing risk, and supports investment or restructuring capacity over the medium term.
Cash GenerationStrong operating and free cash flow in 2025 demonstrates the business can convert revenue into cash even while accounting earnings were weak. Sustainable cash generation supports capex, debt reduction and operational resilience, improving long-term funding options and strategic optionality.
Service Platform / Market FocusA dual-focus on medical aesthetics and eye-care creates a diversified consumer-facing service platform with repeat procedures and cross-sell potential. Structural demand for elective and ophthalmic care supports recurring revenue opportunities and scalable clinic-level margins over multiple years.
Bears Say
Declining RevenueA sustained and material top-line decline reduces operating scale and weakens fixed-cost coverage, pressuring margins and cash flows. Continued revenue contraction undermines the firm's ability to invest in growth, maintain clinic networks, and sustain competitive positioning over a 2–6 month horizon.
Unstable ProfitabilityEarnings have swung between strong and negative results, with 2025 showing a net loss despite operating profit. This volatility reduces predictability of returns, complicates capital allocation and dividend prospects, and raises execution risk for management planning and investor confidence.
Volatile Cash Flow HistoryHistoric swings in operating and free cash flow mean the 2025 rebound may not be durable. Cyclical or execution-sensitive cash conversion undermines liquidity planning, increases dependency on external funding during downturns, and raises the chance of constrained investment in adverse periods.
Yestar Healthcare Holdings Co Ltd News
2393 FAQ
What was Yestar Healthcare Holdings Co Ltd’s price range in the past 12 months?
Yestar Healthcare Holdings Co Ltd lowest stock price was HK$0.07 and its highest was HK$0.20 in the past 12 months.
What is Yestar Healthcare Holdings Co Ltd’s market cap?
Yestar Healthcare Holdings Co Ltd’s market cap is HK$174.72M.
When is Yestar Healthcare Holdings Co Ltd’s upcoming earnings report date?
Yestar Healthcare Holdings Co Ltd’s upcoming earnings report date is Aug 27, 2026 which is in 74 days.
How were Yestar Healthcare Holdings Co Ltd’s earnings last quarter?
Yestar Healthcare Holdings Co Ltd released its earnings results on Mar 27, 2026. The company reported -HK$0.038 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.038.
Is Yestar Healthcare Holdings Co Ltd overvalued?
According to Wall Street analysts Yestar Healthcare Holdings Co Ltd’s price is currently Overvalued.
Does Yestar Healthcare Holdings Co Ltd pay dividends?
Yestar Healthcare Holdings Co Ltd pays a Annually dividend of HK$0.055 which represents an annual dividend yield of N/A. See more information on Yestar Healthcare Holdings Co Ltd dividends here
What is Yestar Healthcare Holdings Co Ltd’s EPS estimate?
Yestar Healthcare Holdings Co Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Yestar Healthcare Holdings Co Ltd have?
Yestar Healthcare Holdings Co Ltd has 2,331,590,000 shares outstanding.
What happened to Yestar Healthcare Holdings Co Ltd’s price movement after its last earnings report?
Yestar Healthcare Holdings Co Ltd reported an EPS of -HK$0.038 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.02%.
Which hedge fund is a major shareholder of Yestar Healthcare Holdings Co Ltd?
Currently, no hedge funds are holding shares in HK:2393
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Yestar Healthcare Holdings Co Ltd Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
44.31%
12-Months-Change
Fundamentals
Return on Equity
-17.70%
Trailing 12-Months
Asset Growth
-12.60%
Trailing 12-Months
Company Description
Yestar Healthcare Holdings Co Ltd
Yestar Healthcare Holdings Company Limited functions as an investment holding entity primarily dedicated to the creation, distribution, and sale of medical imaging goods across mainland China. The company's operations are divided into two principal segments: Imaging Printing Products and Medical Products and Equipment. The Imaging Printing Products division manufactures and supplies items such as Fujifilm color photographic paper, industrial non-destructive testing (NDT) X-ray films, and PWB films. It also trades in various types of imaging equipment. These offerings are employed in both professional and minilab environments, as well as for a range of industrial imaging applications. The NDT X-ray films are specifically marketed under the 'Yes!Star' brand. Conversely, the Medical Products and Equipment segment produces and delivers medical dry and wet films, in addition to dental films. This segment also commercially provides medical equipment and diagnostic reagents, and is engaged in the distribution of in vitro diagnostic products. Furthermore, Yestar Healthcare is involved in biotechnology development initiatives, oversees supply chain management, and offers freight transportation services. Established in 1971, the company operated under the name Yestar International Holdings Company Limited until it adopted its current designation in January 2017. Its corporate headquarters are situated in Shanghai, People's Republic of China.
Technical Analysis
Peijia Medical Ltd.
―
Acotec Scientific Holdings Limited
―
Vincent Medical Holdings Limited
―
Sisram Medical Ltd.
―
Venus Medtech (Hangzhou), Inc. Class H
―